Summary
We will revolutionise the medical field by replacing expensive, invasive and high-risk open-heart surgery, with “keyhole” minimally invasive surgery (MIS) to treat coronary artery disease (CAD). Our ELANA® technology enables reproducible coronary artery bypass grafting (CABG) surgery
without the need of heart arrest and suturing, thus avoiding the need to open the patient’s chest. This is realised with an innovative clip which circumvents the need of suturing of blood vessels altogether. By realising closed-chest CABG, ELANA® reduces not only the risks associated with
traditional CABG, such as bleeding, stroke and wound infection, but also significantly shortens recovery times. As a result, ELANA® will reduce direct healthcare costs of CABG procedures by over 50%. To critically de-risk our technological development and accelerate market entry to 2025, AMT
Medical seeks a total of €7.5M funding (€2.5M grant, €5M equity) to finalise clinical validation and gain market approval.
without the need of heart arrest and suturing, thus avoiding the need to open the patient’s chest. This is realised with an innovative clip which circumvents the need of suturing of blood vessels altogether. By realising closed-chest CABG, ELANA® reduces not only the risks associated with
traditional CABG, such as bleeding, stroke and wound infection, but also significantly shortens recovery times. As a result, ELANA® will reduce direct healthcare costs of CABG procedures by over 50%. To critically de-risk our technological development and accelerate market entry to 2025, AMT
Medical seeks a total of €7.5M funding (€2.5M grant, €5M equity) to finalise clinical validation and gain market approval.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190101904 |
| Start date: | 01-10-2022 |
| End date: | 30-09-2024 |
| Total budget - Public funding: | 3 614 062,50 Euro - 2 497 469,00 Euro |
Cordis data
Original description
We will revolutionise the medical field by replacing expensive, invasive and high-risk open-heart surgery, with “keyhole” minimally invasive surgery (MIS) to treat coronary artery disease (CAD). Our ELANA® technology enables reproducible coronary artery bypass grafting (CABG) surgerywithout the need of heart arrest and suturing, thus avoiding the need to open the patient’s chest. This is realised with an innovative clip which circumvents the need of suturing of blood vessels altogether. By realising closed-chest CABG, ELANA® reduces not only the risks associated with
traditional CABG, such as bleeding, stroke and wound infection, but also significantly shortens recovery times. As a result, ELANA® will reduce direct healthcare costs of CABG procedures by over 50%. To critically de-risk our technological development and accelerate market entry to 2025, AMT
Medical seeks a total of €7.5M funding (€2.5M grant, €5M equity) to finalise clinical validation and gain market approval.
Status
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATOROPEN-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
